Other

Vertex Pharmaceuticals·Income Statement·85 metrics

Breakdown

Loading...

Metrics

Capital Expenditures

Change in Accounts Receivable

Change in Other Liabilities

Tax Withholding for Share-Based Payments

Income Taxes Paid, Net

Interest Paid, Net

Advertising costs

Amortization of capitalized software and acquired intangible assets

Software amortization expense

Common stock, number of votes per share

Federal

Foreign

Federal

Deferred taxes

State

Maximum percentage of annual compensation contributed by the participant (percent)

Depreciation

Income taxes at U.S. statutory rate of 21%

Effective Income Tax Rate Reconciliation, Cross-Border, Other, Amount

Subpart F income, net of credits

Subpart F income, net of credits

Other

Deferred charges related to intra-entity transfers

Deferred charges related to intra-entity transfers

Effective Income Tax Rate Reconciliation, FDII, Amount

Effective Income Tax Rate Reconciliation, FDII, Percent

Foreign operations

Non-deductible AIPR&D

Other

U.S. tax on foreign earnings, net of credits

State income taxes – net of federal income tax benefit

Changes in unrecognized tax benefits

Gain (Loss), Foreign Currency Transaction, before Tax

Federal taxes

State taxes

Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount

Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount

Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount

Changes in unrecognized tax benefits

Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount

Effective Income Tax Rate Reconciliation, Tax Exempt Income, Amount

Income Taxes Paid, Net

Accounts payable

Increase (Decrease) in Accounts Receivable

Increase in accrued expenses and other liabilities

Increase (Decrease) in Inventories

Other liabilities

Increase (Decrease) in Prepaid Expense and Other Assets

Interest Paid, Excluding Capitalized Interest, Operating Activity

Net interest and investment income (loss)

Cash Provided by (Used in) Financing Activity, Including Discontinued Operation

Cash Provided by (Used in) Investing Activity, Including Discontinued Operation

Cash Provided by (Used in) Operating Activity, Including Discontinued Operation

Net payments due to CRISPR Therapeutics AG related to finite-lived intangible assets

Operating Lease Payments

Other Noncash Income (Expense)

Other income, net (Note 6)

Payment for (Proceeds from) Other Investing Activity

Payments for Repurchase of Common Stock

Payment, Tax Withholding, Share-Based Payment Arrangement

Payments to Acquire Debt Securities, Available-for-Sale

Payments to Acquire Property, Plant, and Equipment

Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options

Financing — other

Proceeds from sales and redemptions of investments in debt securities classified as available for sale

Cash received from option exercises

Property, Plant and Equipment, Gross, Period Increase (Decrease)

Reduction to finance leases

Research and development expense

Revenue

Stock-based compensation

Granted (in shares)

Intrinsic value of stock options exercised

Granted (in shares)

Exercised (in shares)

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period

Stock Repurchased During Period Shares

Unrecognized tax benefits, settlements

Unrecognized Tax Benefits, Decrease Resulting from Foreign Currency Translation

Unrecognized tax benefits, deferred tax liabilities, gross

Interest expense and penalties, net (benefit)/charge recognized

Unrecognized tax benefits, increase (decrease) in deferred tax assets, gross

Foreign currency effect

Additions for tax positions of prior years

Increase (decrease) in amount of unrecognized tax benefits